| Identification | Back Directory | [Name]
3H-Imidazo[4,5-b]pyridine-5-carboxylic acid, 2-[[4-[(3S)-3-(4-chloro-2-fluorophenyl)-2,3-dihydro-1,4-benzodioxin-5-yl]-1-piperidinyl]methyl]-3-[(2S)-2-oxetanylmethyl]- | [CAS]
2736447-04-2 | [Synonyms]
GLP-1 receptor agonist 7
3H-Imidazo[4,5-b]pyridine-5-carboxylic acid, 2-[[4-[(3S)-3-(4-chloro-2-fluorophenyl)-2,3-dihydro-1,4-benzodioxin-5-yl]-1-piperidinyl]methyl]-3-[(2S)-2-oxetanylmethyl]- | [Molecular Formula]
C31H30ClFN4O5 | [MOL File]
2736447-04-2.mol | [Molecular Weight]
593.05 |
| Chemical Properties | Back Directory | [Boiling point ]
753.0±60.0 °C(Predicted) | [density ]
1.52±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
7.38±0.10(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Uses]
GLP-1 receptor agonist 7 is a potent agonist of glucagon-like peptide-1 (GLP-1). GLP-1 receptor agonist 7 has the potential for the research of GLP-1-associated diseases, disorders, and conditions including diabetes mellitus (extracted from patent WO2021219019A1, compound 130b)[1]. | [References]
[1] Qinghua Meng, et al. Heterocyclic glp-1 agonists. Patent WO2021219019A1. |
|
|